Neumora Therapeutics (NMRA) Competitors $1.50 -0.02 (-1.32%) Closing price 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, QURE, ATAI, and CRONShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group Neumora Therapeutics (NASDAQ:NMRA) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Do analysts recommend NMRA or UPB? Neumora Therapeutics currently has a consensus target price of $7.14, indicating a potential upside of 376.19%. Upstream Bio has a consensus target price of $56.50, indicating a potential upside of 225.65%. Given Neumora Therapeutics' higher possible upside, equities analysts clearly believe Neumora Therapeutics is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, NMRA or UPB? Upstream Bio has higher revenue and earnings than Neumora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.57-0.96Upstream Bio$2.37M394.66-$62.81MN/AN/A Does the media refer more to NMRA or UPB? In the previous week, Neumora Therapeutics had 5 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Neumora Therapeutics and 3 mentions for Upstream Bio. Neumora Therapeutics' average media sentiment score of 1.30 beat Upstream Bio's score of 0.94 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Upstream Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NMRA or UPB more profitable? Neumora Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -98.95% -87.68% Upstream Bio -3,836.58%-35.90%-26.26% Do institutionals & insiders believe in NMRA or UPB? 47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryNeumora Therapeutics and Upstream Bio tied by winning 6 of the 12 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.92M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.9621.3075.8626.51Price / SalesN/A379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book0.849.6112.846.32Net Income-$243.79M-$53.28M$3.28B$270.51M7 Day Performance-10.18%0.30%0.20%2.15%1 Month Performance-7.98%4.57%4.59%6.35%1 Year Performance-87.44%9.23%68.31%25.48% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.9979 of 5 stars$1.50-1.3%$7.14+376.2%-87.4%$242.92MN/A-0.96108News CoveragePositive NewsAnalyst DowngradeUPBUpstream Bio1.5385 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038SIONSionna Therapeutics2.8244 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035Gap UpHigh Trading VolumeORICOric Pharmaceuticals4.558 of 5 stars$10.50-3.5%$17.29+64.6%+8.3%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.213 of 5 stars$14.80-3.0%$30.00+102.7%+82.9%$1.05B$297.20M-113.85280News CoverageGap UpSYRESpyre Therapeutics2.4449 of 5 stars$16.63-2.2%$53.40+221.1%-49.5%$1.03B$890K-4.8973News CoverageAnalyst ForecastSPRYARS Pharmaceuticals2.4898 of 5 stars$10.70+6.3%$32.50+203.7%-25.1%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.2973 of 5 stars$40.75-13.0%$85.88+110.7%-32.4%$985.99M$8.55M-3.32110Positive NewsHigh Trading VolumeQUREuniQure3.2761 of 5 stars$17.43-2.9%$37.45+114.9%+162.2%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.8818 of 5 stars$4.52-1.1%$11.25+148.9%+257.7%$979.53M$310K-6.5580CRONCronos Group2.4477 of 5 stars$2.48-0.8%N/A+17.0%$957.23M$117.61M49.60450 Related Companies and Tools Related Companies Upstream Bio Competitors Sionna Therapeutics Competitors Oric Pharmaceuticals Competitors Pharming Group Competitors Spyre Therapeutics Competitors ARS Pharmaceuticals Competitors Praxis Precision Medicines Competitors uniQure Competitors atai Life Sciences Competitors Cronos Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
